Publication
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (21)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 21
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- cancerMelanomacivic_curation1.00
- cancerNeuroblastomacivic_curation1.00
- cancerSolid Neoplasmcivic_curation1.00
- drugEntrectinibcivic_curation1.00
- geneALKcivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK2civic_curation1.00
- geneNTRK3civic_curation1.00
- geneROS1civic_curation1.00
- variantALK F1245Vcivic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantNTRK1 Amplificationcivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK2 Amplificationcivic_curation1.00
- variantNTRK3 Amplificationcivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
- variantROS1 Fusioncivic_curation1.00
- variantROS1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (9)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28183697
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK1 Fusion1 | ||||||||
| Entrectinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2950Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Entrectinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID2951Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrec… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| NTRK1 Amplification + NTRK2 Amplification + NTRK3 AmplificationNTRK1NTRK3NTRK21 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 1 | accepted | EID2958Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| NTRK3 Amplification1 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | B | Does Not Support Sensitivity Response | 1 | accepted | EID2959Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2952Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| Entrectinib | Malignant NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2949in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the a… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| ROS1 Fusion1 | ||||||||
| Entrectinib | Melanoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID12140Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrec… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| ALK F1245V1 | ||||||||
| Entrectinib | Neuroblastoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID2987Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. T… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Entrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID2948The overall safety and antitumor activity of entrectinib was described for two phase I trials of patients with advanced solid tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions. NTRK1 fusions were … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC | civic |